MedTrace Logo

Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET

NCT02801591 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2016-06-16

No results posted yet for this study

Summary

Observe the clinical efficacy and safety of Recombinant Human Growth Hormone Injection assisted in the treatment of the patients with poor ovarian response in vitro fertilization and embryo transfer.

Conditions

  • Poor Ovarian Response

Interventions

PROCEDURE

Conventional ovarian stimulation proctol without rhGH

Sponsors & Collaborators

  • Peking University Third Hospital

    collaborator OTHER

  • Peking University People's Hospital

    collaborator OTHER

  • Changchun GeneScience Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xin Na Chen · Peking University Third Hospital

Eligibility

Min Age
30 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-02-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02801591 on ClinicalTrials.gov